STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Boudadi, Karim
Suzman, Daniel L.
Luber, Brandon
Wang, Hao
Silberstein, John L.
Taylor, Maritza N.
Sullivan, Rana
Dowling, Donna
Harb, Rana
Dittamore, Ryan Vance
Meeker, Alan
Luo, Jun
Drake, Charles G.
Antonarakis, Emmanuel S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[4] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Marriottsville, MD USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Epic Sci, San Diego, CA USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5089
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
    Schlack, Katrin
    Seitzer, Konstantin
    Wuestmann, Neele
    Humberg, Verena
    Grundmann, Norbert
    Steinestel, Julie
    Tiedje, Dorothee
    Rahbar, Kambiz
    Krabbe, Laura-Maria
    Boegemann, Martin
    Schrader, Andres J.
    Bernemann, Christof
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    Gao, Xin
    Burris, Howard A., III
    Vuky, Jacqueline
    Dreicer, Robert
    Sartor, A. Oliver
    Sternberg, Cora N.
    Percent, Ivor John
    Hussain, Maha H. A.
    Kalebasty, Arash Rezazadeh
    Shen, John
    Heath, Elisabeth I.
    Abesada-Terk, Guillermo
    Gandhi, Sunil G.
    McKean, Meredith
    Lu, Haolan
    Berghorn, Elmer
    Gedrich, Richard
    Chirnomas, S. Debbie
    Vogelzang, Nicholas J.
    Petrylak, Daniel P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Stewart, Tyler F.
    Gao, Xin
    Berghorn, Elmer
    Lu, Haolan
    Chan, Edward
    Gedrich, Richard
    Lang, Joshua Michael
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [24] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Zhao, J. L.
    Antonarakis, S.
    Cheng, H.
    George, D. J.
    Aggarwal, R. R.
    Abida, W.
    Decker, B.
    Smart-Curley, T.
    Schonhoft, J.
    Anderson, A.
    Haywood, S.
    Riedel, E.
    Carver, B.
    Wyatt, A.
    Feng, F.
    Knudsen, K.
    Rathkopf, D. E.
    ANNALS OF ONCOLOGY, 2021, 32 : S643 - S644
  • [26] Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Chen, Yan
    Roeser, Jeffrey C.
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing Judith
    Denmeade, Samuel R.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Luo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Markowski, Mark Christopher
    Silberstein, John
    Eshleman, James R.
    Luo, Jun
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [28] A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Danila, Daniel Costin
    Waterhouse, David Michael
    Appleman, Leonard Joseph
    Pook, David William
    Matsubara, Nobuaki
    Dorff, Tanya B.
    Lee, Jae-Lyun
    Armstrong, Andrew J.
    Kim, Miso
    Horvath, Lisa
    Sumey, Christopher Joseph
    Cooner, Freda
    Salvati, Mark
    Stieglmaier, Julia
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC)
    Burns, Michael C.
    Sagar, Vinay
    Jovanovic, Borko
    Morgans, Alicia K.
    VanderWeele, David James
    Quinn, David I.
    Stadler, Walter Michael
    Abdulkadir, Sarki
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] Phase II cohort study in patients with metastatic castration-resistant prostate cancer (mCRPC) with new cohorts
    Rexer, Heidrun
    Retz, Margitta
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (06) : 504 - 505
12345